Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity

Mohamed A. El-Moselhy, Azza A.K. El-Sheikh

Research output: Contribution to journalArticleResearchpeer-review

46 Citations (Scopus)

Abstract

To investigate the mechanisms by which the anticancer drug doxorubicin (DOX)-induced hepato-renal damage could be prevented by the cholesterol-lowering statin, atorvastatin (Ator), Ator (10. mg/kg) was administered orally for 10. days, and, in independent rat groups, DOX hepato-renal toxicity was induced via a single i.p. dose of 15. mg/kg at day 5 of experiment, with or without Ator. DOX caused deterioration in hepato-renal function, as it significantly increased blood urea nitrogen (BUN), creatinine, alanine transaminase (ALT) and aspartate transaminase (AST) compared to control, with distortion in normal renal and hepatic histology. Pretreatment with Ator preserved kidney and liver function and histology. DOX caused oxidative stress as indicated by significant decrease in reduced glutathione (GSH) level and catalase activity with increase in malondialdehyde (MDA) compared to control. Combined DOX/Ator significantly reversed these values compared to DOX in both kidney and liver. DOX caused nitrosative stress, as it increased tissue nitric oxide compared to control. Concomitant DOX/Ator treatment decreased NO in kidney and liver. Furthermore, DOX caused inflammatory effects indicated by up-regulation of hepato-renal nuclear factor-κB (NF-κB) expression and increment of tumor necrosis factor-α (TNF-α) tissue concentration, with down-regulation of endothelial nitric oxide synthase (eNOS). DOX also caused apoptotic effect, as it up-regulated the apoptotic marker, Bcl-2-associated X protein (Bax), expression in liver and kidney. Using Ator with DOX reversed hepato-renal inflammatory and apoptotic marker expression. These findings suggest Ator as a protective adjuvant against DOX toxicity, via antioxidant, anti-nitrosative, anti-inflammatory and anti-apoptotic mechanisms.

Original languageEnglish
Pages (from-to)101-110
Number of pages10
JournalBiomedicine and Pharmacotherapy
Volume68
Issue number1
DOIs
Publication statusPublished - 1 Feb 2014

Fingerprint

Doxorubicin
Kidney
Liver
Atorvastatin Calcium
Histology
Hydroxymethylglutaryl-CoA Reductase Inhibitors
bcl-2-Associated X Protein
Nitric Oxide Synthase Type III
Blood Urea Nitrogen
Aspartate Aminotransferases
Malondialdehyde
Alanine Transaminase
Catalase
Glutathione
Creatinine
Nitric Oxide
Oxidative Stress
Anti-Inflammatory Agents
Up-Regulation
Down-Regulation

Keywords

  • Atorvastatin
  • Doxorubicin
  • Oxidative stress

Cite this

@article{31111836d17f459d87fb9bb3067d8a55,
title = "Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity",
abstract = "To investigate the mechanisms by which the anticancer drug doxorubicin (DOX)-induced hepato-renal damage could be prevented by the cholesterol-lowering statin, atorvastatin (Ator), Ator (10. mg/kg) was administered orally for 10. days, and, in independent rat groups, DOX hepato-renal toxicity was induced via a single i.p. dose of 15. mg/kg at day 5 of experiment, with or without Ator. DOX caused deterioration in hepato-renal function, as it significantly increased blood urea nitrogen (BUN), creatinine, alanine transaminase (ALT) and aspartate transaminase (AST) compared to control, with distortion in normal renal and hepatic histology. Pretreatment with Ator preserved kidney and liver function and histology. DOX caused oxidative stress as indicated by significant decrease in reduced glutathione (GSH) level and catalase activity with increase in malondialdehyde (MDA) compared to control. Combined DOX/Ator significantly reversed these values compared to DOX in both kidney and liver. DOX caused nitrosative stress, as it increased tissue nitric oxide compared to control. Concomitant DOX/Ator treatment decreased NO in kidney and liver. Furthermore, DOX caused inflammatory effects indicated by up-regulation of hepato-renal nuclear factor-κB (NF-κB) expression and increment of tumor necrosis factor-α (TNF-α) tissue concentration, with down-regulation of endothelial nitric oxide synthase (eNOS). DOX also caused apoptotic effect, as it up-regulated the apoptotic marker, Bcl-2-associated X protein (Bax), expression in liver and kidney. Using Ator with DOX reversed hepato-renal inflammatory and apoptotic marker expression. These findings suggest Ator as a protective adjuvant against DOX toxicity, via antioxidant, anti-nitrosative, anti-inflammatory and anti-apoptotic mechanisms.",
keywords = "Atorvastatin, Doxorubicin, Oxidative stress",
author = "El-Moselhy, {Mohamed A.} and El-Sheikh, {Azza A.K.}",
year = "2014",
month = "2",
day = "1",
doi = "10.1016/j.biopha.2013.09.001",
language = "English",
volume = "68",
pages = "101--110",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",
number = "1",

}

Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity. / El-Moselhy, Mohamed A.; El-Sheikh, Azza A.K.

In: Biomedicine and Pharmacotherapy, Vol. 68, No. 1, 01.02.2014, p. 101-110.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity

AU - El-Moselhy, Mohamed A.

AU - El-Sheikh, Azza A.K.

PY - 2014/2/1

Y1 - 2014/2/1

N2 - To investigate the mechanisms by which the anticancer drug doxorubicin (DOX)-induced hepato-renal damage could be prevented by the cholesterol-lowering statin, atorvastatin (Ator), Ator (10. mg/kg) was administered orally for 10. days, and, in independent rat groups, DOX hepato-renal toxicity was induced via a single i.p. dose of 15. mg/kg at day 5 of experiment, with or without Ator. DOX caused deterioration in hepato-renal function, as it significantly increased blood urea nitrogen (BUN), creatinine, alanine transaminase (ALT) and aspartate transaminase (AST) compared to control, with distortion in normal renal and hepatic histology. Pretreatment with Ator preserved kidney and liver function and histology. DOX caused oxidative stress as indicated by significant decrease in reduced glutathione (GSH) level and catalase activity with increase in malondialdehyde (MDA) compared to control. Combined DOX/Ator significantly reversed these values compared to DOX in both kidney and liver. DOX caused nitrosative stress, as it increased tissue nitric oxide compared to control. Concomitant DOX/Ator treatment decreased NO in kidney and liver. Furthermore, DOX caused inflammatory effects indicated by up-regulation of hepato-renal nuclear factor-κB (NF-κB) expression and increment of tumor necrosis factor-α (TNF-α) tissue concentration, with down-regulation of endothelial nitric oxide synthase (eNOS). DOX also caused apoptotic effect, as it up-regulated the apoptotic marker, Bcl-2-associated X protein (Bax), expression in liver and kidney. Using Ator with DOX reversed hepato-renal inflammatory and apoptotic marker expression. These findings suggest Ator as a protective adjuvant against DOX toxicity, via antioxidant, anti-nitrosative, anti-inflammatory and anti-apoptotic mechanisms.

AB - To investigate the mechanisms by which the anticancer drug doxorubicin (DOX)-induced hepato-renal damage could be prevented by the cholesterol-lowering statin, atorvastatin (Ator), Ator (10. mg/kg) was administered orally for 10. days, and, in independent rat groups, DOX hepato-renal toxicity was induced via a single i.p. dose of 15. mg/kg at day 5 of experiment, with or without Ator. DOX caused deterioration in hepato-renal function, as it significantly increased blood urea nitrogen (BUN), creatinine, alanine transaminase (ALT) and aspartate transaminase (AST) compared to control, with distortion in normal renal and hepatic histology. Pretreatment with Ator preserved kidney and liver function and histology. DOX caused oxidative stress as indicated by significant decrease in reduced glutathione (GSH) level and catalase activity with increase in malondialdehyde (MDA) compared to control. Combined DOX/Ator significantly reversed these values compared to DOX in both kidney and liver. DOX caused nitrosative stress, as it increased tissue nitric oxide compared to control. Concomitant DOX/Ator treatment decreased NO in kidney and liver. Furthermore, DOX caused inflammatory effects indicated by up-regulation of hepato-renal nuclear factor-κB (NF-κB) expression and increment of tumor necrosis factor-α (TNF-α) tissue concentration, with down-regulation of endothelial nitric oxide synthase (eNOS). DOX also caused apoptotic effect, as it up-regulated the apoptotic marker, Bcl-2-associated X protein (Bax), expression in liver and kidney. Using Ator with DOX reversed hepato-renal inflammatory and apoptotic marker expression. These findings suggest Ator as a protective adjuvant against DOX toxicity, via antioxidant, anti-nitrosative, anti-inflammatory and anti-apoptotic mechanisms.

KW - Atorvastatin

KW - Doxorubicin

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=84895070765&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2013.09.001

DO - 10.1016/j.biopha.2013.09.001

M3 - Article

VL - 68

SP - 101

EP - 110

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 1

ER -